Literature DB >> 7603146

Drug therapy.

P A Rochon1, J H Gurwitz.   

Abstract

Drug therapy for individuals of any age is difficult but prescribing for older patients offers special challenges. Older people take about three times as many prescription medications as younger individuals do, mainly because of their increased prevalence of chronic medical conditions. However, taking several drugs together substantially increases the risk of drug interactions, unwanted effects, and adverse reactions. Many medications need to be used with special caution because of age-related changes in pharmacokinetics and pharmacodynamics. For some drugs, an increase in the volume of distribution (eg, diazepam) or a reduction in drug clearance (eg, digoxin) may lead to higher plasma concentrations in older than in younger patients. Pharmacodynamic changes with ageing may result in an increased sensitivity to the effects of certain drugs (eg, opioids) for any given plasma concentration. While a physician can usually do little to alter the characteristics of individual older patients to affect the kinetics or dynamics of drugs, the decision whether to prescribe anything at all, the choice of drug, and the manner in which it is to be used (eg, dose and duration of therapy) are all factors that are under control of the prescriber. Patient adherence to the regimen prescribed is important, and there should be a partnership between physician and patient in therapeutic decision making. We will discuss here ways of improving prescribing for older patients. Specifically, we will examine the scarcity of information to guide prescribing decisions, the general principles of prudent prescribing, and the opportunities to clarify and expand knowledge about drug therapy in the elderly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603146     DOI: 10.1016/s0140-6736(95)92656-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Optimal medication use in elders. Key to successful aging.

Authors:  M Monane; S Monane; T Semla
Journal:  West J Med       Date:  1997-10

Review 2.  Revisiting the O complex: urinary incontinence, delirium and polypharmacy in elderly patients.

Authors:  D B Hogan
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

3.  "Iatrogenicity cascade": doing harm by treating harm?

Authors:  Claudia Christina Wagner; Jerome Biollaz; Markus Zeitlinger; Thierry Buclin
Journal:  Wien Med Wochenschr       Date:  2009

4.  Factors affecting access to drug therapy in the elderly.

Authors:  H Dombrower; T A Izukawa; S L Veinish
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

Review 5.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 6.  Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?

Authors:  Giuseppe Sergi; Marina De Rui; Silvia Sarti; Enzo Manzato
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

7.  Prevalence and determinants of anticholinergic medication use in elderly dementia patients.

Authors:  Sneha D Sura; Ryan M Carnahan; Hua Chen; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

8.  Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study.

Authors:  Nathalie Lechevallier-Michel; Mathieu Molimard; Jean-François Dartigues; Colette Fabrigoule; Annie Fourrier-Réglat
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

9.  Is it possible to reduce polypharmacy in the elderly? A randomised, controlled trial.

Authors:  K H Pitkala; T E Strandberg; R S Tilvis
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 10.  Drug therapy and the older person: role of the pharmacist.

Authors:  M J Denham; N L Barnett
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.